Qiagen N.V. (QGEN)

Market Cap	8.55B
Revenue (ttm)	1.98B
Net Income (ttm)	83.59M
Shares Out	216.12M
EPS (ttm)	0.38
PE Ratio	103.97
Forward PE	17.30
Dividend	$1.32 (3.34%)
Ex-Dividend Date	Jan 29, 2025

Volume	1,257,210
Open	39.21
Previous Close	38.57
Day's Range	38.80 - 39.59
52-Week Range	38.49 - 47.93
Beta	0.36
Analysts	Buy
Price Target	49.79 (+25.83%)
Earnings Date	Feb 5, 2025

About QGEN

Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Analyst Forecast

According to 8 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $49.79, which is an increase of 25.83% from the latest price.

Price Target

$49.79

(25.83% upside)

Analyst Consensus: Buy